INTERVIEWS

Norman E. Rosenthal is a psychiatrist and scientist who first described SAD in 1984 and pioneered light therapy as a treatment. Dr. Rosenthal is currently Clinical Professor of Psychiatry at Georgetown University School of Medicine and the author of several books, his most recent being Defeating SAD (Seasonal Affective Disorder): A Guide to Health and Happiness Through All Seasons

Chad Worz, PharmD, BCGP, FASCP, Executive Director and Chief Executive Officer of the American Society of Consultant Pharmacists (ASCP) discusses a new flu vaccination campaign from the ASCP and Sanofi that encourages older adults and those with chronic conditions to speak with their healthcare providers or pharmacists about flu vaccine options that may be right for them.

Dr. Steven Quay, Chairman of the Board and CEO of Atossa Therapeutics, a company focused on preventing breast cancer in at-risk women and treating breast cancer in women of all ages, discusses the development of a drug called (z)-endoxifen for breast cancer treatment which is currently undergoing 3 separate phase 2 clinical trials in the US.

Sujal Shah, President and CEO of CymaBay Therapeutics, a clinical-stage biopharmaceutical company, discusses the positive topline results from its Phase 3 pivotal RESPONSE study of seladelpar in patients with primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease. This is the first potential therapy to show promise in significantly improving markers associated with risk of disease progression and significantly reducing itch.

Michelle Wulfestieg, Executive Director at Southern California Hospice Foundation and CEO of Heavenly Home discusses how she is fighting the battle of homelessness for the terminally ill and how she is accepting those at Heavenly Home who may lack financial resources and have no other options for end-of-life care.

Arun Krishna, VP, Head of Lung Cancer Franchise, US Oncology Business Unit at AstraZeneca discusses the positive results from the FLAURA2 Phase III trial of TAGRISSO ® (osimertinib) plus chemotherapy and its significance as a new potential treatment option for patients with advanced lung cancer.

Returning guest, Dr. Paul Limburg, Chief Medical Officer, Screening at Exact Sciences discusses recent research that revealed countless reasons why 45-year-olds in the U.S. aren’t getting screened for this deadly condition despite recommendations by national screening guidelines. He talks more about how screening can change the course of this deadly disease.

Tracy Curley, the CEO of iSpecimen, an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, discusses the iSpecimen platform, the importance of just-in-time biobanking and what’s up next for the industry. 

Dr. Deepak Bhatt, MD, MPH, Director of Mount Sinai Heart and Principal Study Author discusses the final dataset from the Phase 2 ENTRIGUE trial of 89bio’s pegozafermin in patients with severe hypertriglyceridemia (SHTG) that was published online in “Nature Medicine” (June 24, 2023). To learn more about pegozafermin’s indications in non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG), please visit https://www.89bio.com/pipeline/.

Dr. Comilla Sasson, MD, PhD, Vice President for Healthcare Business Solutions at the American Heart Association and a practicing Emergency Medicine physician in Denver, Colorado discusses AHA’s newly launched Nation of Lifesavers™ initiative to double survival rates from sudden cardiac arrest by 2030. The new multi-year initiative will ensure teens and adults can learn about CPR and AED use, share that knowledge with friends and family and engage employers, policymakers, philanthropists, and others to create support for a nation of lifesavers. She talks about the do’s and don’ts of CPR, including some common misconceptions, and shares some familiar songs from a variety of genres that can help everyone easily keep the correct pace when performing CPR